Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Mylan has restarted production of hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility.
read more
Friday, September 21, 2018
Mylan announced the U.S. launch of Dalfampridine Extended-Release Tablets, 10 mg, the authorized generic version of Acorda's Ampyra.
read more
Mylan announced the U.S. launch of Tadalafil Tablets USP, 20 mg, the first generic version of the reference listed drug, Eli Lilly and Company's Adcirca.
read more
Friday, November 20, 2015
Mylan has announced the U.S. launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity amphetamine product), 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and...
read more
Mylan has announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules.
read more
Mylan has announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen's Concerta® Tablets.
read more
Tuesday, December 29, 2015
Mylan has announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer's Zyvox® Tablets.
read more
Mylan lowered the bar for shareholder approval in its ongoing hostile bid for rival pharmaceutical company Perrigo.
read more
Thursday, November 05, 2015
Mylan has announced that the U.S. Federal Trade Commission has cleared the company's proposed transaction to acquire Perrigo Company subject to Mylan's divestiture of certain products following the consummation of the offer.
read more
Tuesday, September 08, 2020
Mylan announced an agreement to acquire the related intellectual property and commercialization rights of Aspen's thrombosis business in Europe.
read more
Mylan announced a global collaboration with Gilead Sciences to expand access to the investigational antiviral remdesivir for the potential treatment of COVID-19.
read more
Mylan Chairman Robert J. Coury and Chief Executive Officer Heather Bresch provided additional detail regarding the company's efforts to meet public health needs amid the evolving COVID-19 pandemic.
read more
Monday, December 04, 2017
Mylan and Aspen announced the U.S. launch of Myleran Injection, 60 mg/10 mL (6 mg/mL) Single-dose Vial, a generic version of Busulfex Injection.
read more
Mylan and Biocon announced the FDA has approved the NDA for Semglee in vial and pre-filled pen presentations, to control high blood sugar.
read more
Wednesday, April 29, 2020
Mylan and Biocon announced the launch of Fulphila®, a biosimilar to Neulasta® (pegfilgrastim). Fulphila is approved by Health Canada.
read more